Nabriva Therapeutics Plc (NBRV) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Competitors, else..
 
Nabriva Therapeutics Plc  (NASDAQ: NBRV)
 

Nabriva Therapeutics Plc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NBRV Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) -75.6 % -6.11 % -2.2 % -2.46 %
Q / Q Revenue Growth (Q2 MRQ) -70.45 % 1.12 % 1.53 % 1.26 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) -16.35 % -4.27 % -2.33 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) -19.03 % -2.07 % -0.88 % -0.63 %
Revenue 5 Year Average Growth 47.34 % 10.99 % 8.94 % 9.55 %


NBRV's Growth Comparisons in II. Quarter 2023




As Nabriva Therapeutics Plc's sales faded by -75.6% year on year in the second quarter 2023, the Major Pharmaceutical Preparations industry fell only by -6.11%, Nabriva Therapeutics Plc's second quarter 2023 performance was trailing the Major Pharmaceutical Preparations industry in the second quarter 2023, and underperformed the -2.2% Revenue decrease in the Healthcare sector. The Healthcare sector grew above market average, while Major Pharmaceutical Preparations industry and Nabriva Therapeutics Plc results underperformed, in the second quarter.

Top-line fell by -70.45% from the first quarter results. Comparing the annual growth, sales of 47.34% on average in last five years, to the S & P 500's, including only Businesses with the second quarter 2023 financial results, average yearly sales growth is 9.55%. Nabriva Therapeutics Plc grew faster than the market.


Growth Rates of NBRV's Income in the second quarter 2023


NBRV Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - -55.93 % -50.26 % -12.52 %
Sequential Operating Income Change (Q2 MRQ) - -53.55 % -53.3 % -4.07 %
Y / Y Operating Income Growth (Q2 TTM) - -15.55 % -23.02 % -6.7 %
Sequential Operating Income Growth (Q2 TTM) - -15.67 % -12.58 % -3.41 %
Operating Income 5 Year Avg. Change - 15.5 % 4.67 % 8.71 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) - -68.64 % -83.21 % -12.23 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) - -45.13 % -82.44 % -5.88 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) - -41.81 % -47.5 % -9.06 %
Sequential Income from Cont. Ops. Change (Q2 TTM) - -22.19 % -21.26 % -3.4 %
Income from Cont. Ops. 5 Year Avg. Change - 16.52 % 8.32 % 11.88 %

NBRV Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) - -68.74 % -81.74 % -10.4 %
Q / Q Net Income Growth (Q2 MRQ) - -45.06 % -81.23 % -4.29 %
Y / Y Net Income Change (Q2 TTM) - -40.02 % -44.15 % -8.96 %
Sequential Net Income Change (Q2 TTM) - -21.96 % -20.11 % -2.9 %
Net Income 5 Year Avg. Growth - 21.26 % 10.49 % 3.58 %

NBRV's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) - -85.86 % -83.21 % -12.23 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) - -75.9 % -82.44 % -5.88 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) - - - 31714.25 %
EPS from Cont. Ops. 5 Year Avg. Growth - 5.03 % 8.32 % 11.88 %



NBRV EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) - -85.9 % -81.74 % -10.4 %
Q / Q EPS Net Growth (Q2 MRQ) - -75.87 % -81.23 % -4.29 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 22065.17 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) - - - 27229.2 %
EPS Net 5 Year Avg. Change - 21.26 % 10.49 % 3.58 %



Nabriva Therapeutics Plc reported bottom-line of $ -3.73 in the second quarter, compare to $ 0.00 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -85.9%, while Healthcare sector decreased by -81.74%, and overall market declined by -10.4%.

Bottom-line fell by -70.45% from the first quarter results. Comparing the annual growth, income per share of 47.34% on average in last five years, to the S & P 500's, including only Businesses with the second quarter 2023 earnings, average yearly income per share growth is 3.58%. Nabriva Therapeutics Plc grew faster than the market.

NBRV Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) - -42.99 % -25.25 % -22.48 %
Sequential Free Cash Flow Change (Q2 MRQ) - 11.77 % 61 % 98.02 %
Y / Y Free Cash Flow Change (Q2 TTM) - -34.82 % -30.06 % -12.48 %
Sequential Free Cash Flow Change (Q2 TTM) - -13.59 % -7.09 % -8.48 %
Free Cash Flow 5 Year Avg. Change - 8.35 % 6.34 % -24.89 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - -
Sequential Net Cash Flow Change (Q2 MRQ) - - - -
Y / Y Net Cash Flow Change (Q2 TTM) - - - -
Sequential Net Cash Flow Change (Q2 TTM) - - 50.3 % -
Net Cash Flow 5 Year Avg. Change - - -32.87 % 34.23 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) -90.63 % 2.18 % 1.94 % 12.07 %
Sequential Capital Expenditures Change (Q2 MRQ) 100 % -2.47 % -1.72 % 4.78 %
Y / Y Capital Expenditures Change (Q2 TTM) 13.08 % 14.19 % 9.4 % -27.68 %
Sequential Capital Expenditures Change (Q2 TTM) -32.4 % 1.18 % 0.95 % -14.07 %
Capital Expenditures 5 Year Avg. Change -29.04 % 13.35 % 9.54 % 8.4 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.